Top Markets
Coin of the day
Sunshine Biopharma, Inc. Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc.

SBFM
Pozycja w akcjach #39259
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of... Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Cena akcji
$1.16
Ostatnia synchronizacja: 2026-07-31
Kapitalizacja rynkowa
$580.69K
Zmiana (1 dzień)
-5.69%
Zmiana (1 rok)
-92.32%
Kraj
US
Handel Sunshine Biopharma, Inc. (SBFM)

Kategoria

Historia dywidend dla Sunshine Biopharma, Inc. (SBFM)
Sunshine Biopharma, Inc. (symbol giełdowy: SBFM) wypłaciła łącznie 0 dywidend.
Suma wszystkich dywidend (skorygowana o podziały akcji): 0.00
Wskaźnik dywidendy (TTM): 0
Wypłaty dywidend dla Sunshine Biopharma, Inc. (SBFM) od 2026 do 2026
Roczne wypłaty dywidend
Rok Dywidenda (skorygowana o podziały akcji) Zmień
Za mało danych dla podanych dat.
Lista wszystkich wypłat dywidend
Rok Dywidenda Zmień
Za mało danych dla podanych dat.
Wypłaty dywidend firm podobnych lub konkurencyjnych